
Venture capital · Growth stage · Est. 2006
Longitude Capital
Longitude Capital is a healthcare-focused venture growth investor backing biotechnology, medical technology and health solutions companies, in both private and public markets, with offices in Menlo Park and Boston.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is Longitude Capital right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
BetaRounds Longitude Capital joined, from press and the firm’s own posts.
1 round in the last 12 months
Round sizes, Longitude Capital’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company Longitude Capital backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet Longitude Capital
Events where Longitude Capital’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
Longitude Capital is based in Menlo Park, United States. It also has an office in Boston.
In 2006.
6 fund vehicles are on public registers (SEC adviser filings), including LONGITUDE VENTURE PARTNERS IV, L.P., LONGITUDE VENTURE PARTNERS III, L.P. and LONGITUDE VENTURE PARTNERS V, L.P.
Stages: Growth. Sectors: Biotech, Medtech. From the firm’s own website.
Builds a balanced portfolio of clinical- and commercial-stage healthcare companies with clinically de-risked assets and reasonable valuations, targeting returns within three to five years. Sources deals through industry networks and thematic research, uses flexible structures, and works with management and syndicate partners on strategy, hiring and capital raising. From the firm’s own website.
Longitude Capital lists 70 portfolio companies on its website, including 89bio, AEON Biopharma, Aimmune Therapeutics, AirNexis Therapeutics and Akebia Therapeutics.
Firms whose websites list some of the same companies include Frazier Life Sciences, RA Capital and Alta Partners.
Know before Longitude Capital’s next round is announced.
PRO tracks Longitude Capital’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.